Sign up to save your podcasts
Or
Share Phase II Study SECOMBIT (Sequential Combo Immuno and Target Therapy Study): 4-Years OS Data and Preliminary Biomarkers Evaluation
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Phase II Study SECOMBIT (Sequential Combo Immuno and Target Therapy Study): 4-Years OS Data and Preliminary Biomarkers Evaluation
CME credits: 0.75
Valid until: 30-09-2023
Claim your CME credit at https://reachmd.com/programs/cme/phase-ii-study-secombit-sequential-combo-immuno-and-target-therapy-study-4-years-os-data-and-preliminary-biomarkers-evaluation/14453/
This activity provides a summary and analysis of key clinical and scientific data from clinical trials and basic & translational research in melanoma presented at the 2022 European Society of Medical Oncology (ESMO) meeting.
View all episodes
By ReachMD
4.3
33 ratings
CME credits: 0.75
Valid until: 30-09-2023
Claim your CME credit at https://reachmd.com/programs/cme/phase-ii-study-secombit-sequential-combo-immuno-and-target-therapy-study-4-years-os-data-and-preliminary-biomarkers-evaluation/14453/
This activity provides a summary and analysis of key clinical and scientific data from clinical trials and basic & translational research in melanoma presented at the 2022 European Society of Medical Oncology (ESMO) meeting.